Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunoglobulin G - ADMA Biologics

Next Previous
Search
Drug Profile

Immunoglobulin G - ADMA Biologics

Alternative Names: Bivigam; Immunoglobulin liquid intravenous - Biotest Pharmaceuticals; IVIG - Biotest Pharmaceuticals; IVIG - Nabi Biopharmaceuticals; NABI-IVIG

Latest Information Update: 14 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer ADMA Biologics; Biotest Pharmaceuticals; Kedrion
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders

Most Recent Events

  • 14 Dec 2023 US FDA approves sBLA application for Immunoglobulin G in Immunodeficiency disorders (In adults, In Children, In adolescents, In the elderly) in USA (IV)
  • 12 Dec 2023 Registered for Immunodeficiency disorders (In adults, In children, In the elderly, In adolescents) in USA (IV)
  • 27 Mar 2023 ADMA Biologics has patents protection for Immunoglobulin G in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top